Diamyd Medical
Company Details
Status: Public
Employees: 11-50
Location:
Stockholm, Sweden
Type:
sample
Technology:
sample
About: Diamyd Medical is a Swedish diabetes company developing precision medicine therapies for Type 1 Diabetes.
The therapeutic diabetes vaccine Diamyd , an antigen-specific immunotherapy for the preservation of endogenous insulin production, is being evaluated in the ongoing Phase III trial DIAGNODE-3. The company is establishing a vaccine manufacturing facility in Umeå for the manufacture of recombinant GAD65, the active ingredient in the diabetes vaccine. Diamyd Medical also develops the GABA-based investigational drug Remygen® as a therapy for regeneration of endogenous insulin production and to improve hormonal response to hypoglycaemia. Diamyd Medical is one of the major shareholders in the stem cell company NextCell Pharma AB as well as in the artificial intelligence company MainlyAI AB.
The Diamyd Medical share is traded on Nasdaq First North Growth Market, ticker DMYD B.
Unlock access to company contacts, hot leads, and drug pipelines.
Log in or create a free account now!
Diamyd Medical | Active clinical trials on ClinicalTrials.gov
Active Clinical Trials Count | 0
No Active Trials Found On ClinicalTrials.gov.